Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 5/20 | 0.74 |
| ▸ | KDR | P35968 | 3/20 | 0.65 |
| ▸ | CFTR | P13569 | 9/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21162488 | 1.00 | BAZ2B (0.74) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL31117446 | 0.92 | BAZ2B (0.62) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL21588257 | 0.91 | BAZ2B (0.61) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL21114768 | 0.91 | BAZ2B (0.61) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL30506408 | 0.91 | BAZ2B (0.61) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL21154472 | 0.90 | BAZ2B (0.61) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL30228476 | 0.90 | BAZ2B (0.61) | BAZ2BKDRCFTRUSP2CYP1A2 | |
| SCHEMBL21114766 | 0.89 | LMNA (0.62) | BAZ2BKDRCFTRALOX15HSD17B10 | |
| SCHEMBL2832897 | 0.87 | LMNA (0.76) | BAZ2BCFTRUSP2LMNAPABPC1 | |
| SCHEMBL30228387 | 0.87 | TRPV1 (0.59) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367173-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC (KR) | 2025-12-04 | — | — | US | disclosed |
| EP-4540245-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LigaChem Biosciences Inc. (KR) | 2025-04-23 | — | — | EP | disclosed |
| CN-119654323-A | External nucleotide pyrophosphatase-phosphodiesterase-1 inhibitor and pharmaceutical composition containing the same | 瑞嘉化学生物科学股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-109928971-B | Aryl substituted aminotetrahydropyrans and uses thereof | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2023242631-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-12-21 | — | — | WO | disclosed |
| CN-109988106-B | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | 广东东阳光药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367173-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP1, ENPP3, SMPD1 | BAZ2B 3013/4885KDR 2912/4885CFTR 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.